{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-24-000050","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.874756+00:00","generated_at":"2026-06-02T07:04:37.367206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Senti Bio Q1 net loss $12.1M; SENTI-202 patient dosing on track for Q2 2024","bullets":["Cash and equivalents $23.7M at March 31, 2024; additional $18.9M receivable from GeneFab.","Net loss $12.1M ($0.26 per share); R&D expenses rose to $8.8M from $7.1M on manufacturing costs.","SENTI-202 Phase 1 trial for AML on track to dose first patient in Q2 2024; initial efficacy data by year-end 2024.","Pilot trial of SENTI-301A for HCC in China (Celest partnership) expects first patient dosing in Q2 2024.","Presented three abstracts at ASGCT 2024, including novel CAR discovery and engineered synthetic switches."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-24-000050","json":"https://secwatch.observer/filing/0001854270-24-000050.json","markdown":"https://secwatch.observer/filing/0001854270-24-000050.md","text":"https://secwatch.observer/filing/0001854270-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000050/0001854270-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000050/snti-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:04:37.367206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c83c169bf3333800365e4651d3cda8bfb2732980","claim":"Senti Biosciences, Inc. reported first quarter of 2024 results: net income Net loss was $12.1 million, or $0.26 per basic and diluted share, EPS $0.26 per basic and diluted share.","evidence_excerpt":"Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000050/0001854270-24-000050-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Net income","value":"Net loss was $12.1 million, or $0.26 per basic and diluted share"},{"label":"EPS","value":"$0.26 per basic and diluted share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}